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S U M M A R Y
Objective: To compare the prevalence, phenotypes, and genes responsible for erythromycin resistance
among Streptococcus pyogenes isolates from Mexico and the USA.
Methods: Eighty-nine invasive and 378 non-invasive isolates from Mexico, plus 148 invasive, 21 non-
invasive, and ﬁve unclassiﬁed isolates from the USA were studied. Susceptibilities to penicillin,
erythromycin, clindamycin, ceftriaxone, and vancomycin were evaluated according to Clinical and
Laboratory Standards Institute (CLSI) standards. Phenotypes of erythromycin resistance were identiﬁed
by triple disk test, and screening for mefA, ermTR, and ermB genes was carried out by PCR.
Results: All isolates were susceptible to penicillin, ceftriaxone, and vancomycin. Erythromycin resistance
was found in 4.9% of Mexican strains and 5.2% of USA strains. Phenotypes in Mexican strains were 95% M
and 5% cMLS; in strains from the USA, phenotypes were 33.3% iMLS, 33.3% iMLS-D, and 33.3% M.
Erythromycin resistance genes in strains from Mexico were mefA (95%) and ermB (5%); USA strains
harbored ermTR (56%), mefA (33%), and none (11%). In Mexico, all erythromycin-resistant strains were
non-invasive, whereas 89% of strains from the USA were invasive.
Conclusions: Erythromycin resistance continues to exist at low levels in both Mexico and the USA,
although the genetic mechanisms responsible differ between the two nations. These genetic differences
may be related to the invasive character of the S. pyogenes isolated.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Streptococcus pyogenes, or group A streptococcus (GAS), is one of
the most important human pathogens. It has been associated with
both non-invasive infections, such as acute pharyngitis, and
invasive infections, such as cellulitis, necrotizing fasciitis, bacter-
emia, sepsis, and toxic shock syndrome.1§ This manuscript was presented in part at the 111th General Meeting of the
American Society for Microbiology, New Orleans, Louisiana, May 21–24, 2011
(poster C-072).
* Corresponding author. Tel.: +52 33 3668 3000 ext. 31953;
fax: +52 33 3618 1756.
E-mail address: avillase@prodigy.net.mx (A. Villasen˜or-Sierra).
1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.11.005GAS remains very sensitive to penicillin in vitro,2 and this
antibiotic is the drug of choice in the treatment of most
streptococcal infections because of its narrow spectrum, safety,
low cost, and its efﬁcacy in the prevention of rheumatic fever. For
patients allergic to penicillin, erythromycin and other macrolides
are used. For those patients with serious soft tissue infections,
clindamycin is the preferred treatment because of its ability to
inhibit the production of streptococcal virulence factors, including
capsule, M protein, and exotoxins such as NADase and pyrogenic
exotoxin A (SpeA). Clindamycin has also been shown to modulate
both the promitogenic activity of SpeA3 and the host response to
infection.4
Erythromycin inhibits RNA-dependent protein synthesis in
GAS. Different mechanisms of macrolide resistance in GAS haveses. Published by Elsevier Ltd. All rights reserved.
Figure 1. PCR analysis of the erythromycin-resistant strains, using speciﬁc primers
for detection of mefA (lane 1), ermB (lane 2), and ermTR (lane 3). MW = molecular
weight markers.
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membered, but not 16-membered, ring macrolides is encoded by
the mefA or the mefO genes (transposable elements). GAS
possessing this system are said to be of the M phenotype and
are characterized by resistance to erythromycin and susceptibility
to clindamycin.5–7 Another mechanism is decreased binding of
erythromycin, other macrolides, lincosamides and streptogramin
type B (MLSB phenotype) to their targets on the ribosome due to an
altered conformation of a methylase enzyme encoded by two
classes of genes, ermB and ermA subclass TR. MLSB resistance can
be either inducibly (iMLSB phenotype) or constitutively (cMLSB
phenotype) expressed.
Since the 1990s, macrolide resistance has increased worldwide
and ranges between 5% and 78%, with the highest prevalence in
Asia. In America and Europe, the prevalence of macrolide
resistance in GAS strains is around 5%.8
The comparative prevalence, the associated phenotypes, and
the genes responsible for erythromycin resistance in GAS isolates
from invasive and non-invasive infections in Mexico and the USA
are unknown. Thus, the aim of the present study was to compare
these characteristics in such GAS isolates from these neighboring
countries.
2. Materials and methods
2.1. Strains
We studied 467 GAS strains from Mexico and 174 GAS strains
from USA. Strains were identiﬁed as GAS by colony morphology,
the presence of b-hemolysis when plated on 5% sheep blood agar,
sensitivity to bacitracin (0.04 U, TAXO A; BBL Becton Dickinson,
Sparks, MD, USA), and agglutination by speciﬁc antiserum (Slidex
Strepto A; bioMe´rieux).
Susceptibility to penicillin (10 U), erythromycin (15 mg),
clindamycin (2 mg), ceftriaxone (30 mg), and vancomycin
(30 mg) disks (BBL Becton Dickinson, Sparks, MD, USA) was
performed on Mueller–Hinton 5% sheep blood agar plates
(MHSBA) (BBL Becton Dickinson, Sparks, MD, USA) by the
Kirby–Bauer method. Inhibition diameter zones were interpreted
in accordance with the Clinical and Laboratory Standards Institute
guidelines (CLSI; M100-S17, 2010).9 Streptococcus pneumoniae
ATCC 49619 was used for quality control. Strains that showed
resistance to erythromycin using this method were subjected to (1)
a micro-broth dilution test according to the CLSI9 to establish
antibiotic minimum inhibitory concentrations (MIC), and (2) the
triple disk test (erythromycin, clindamycin, and spiramycin)
placed on MHSBA in a triangular manner with 20 mm of separation
between each other, to determine the phenotype of such
resistance.10
2.2. Detection of mefA, ermB, and ermTR genes
All erythromycin-resistant and intermediate strains were
screened for the presence of resistance-related genes. Isolates
were grown for 18 h on MHSBA plates at 37 8C and 5% CO2. A full
loopful of each strain was suspended in 50 ml of lysis buffer (Tris–
HCl, pH 7.6; NaCl; 0.5 M EDTA), boiled at 100 8C for 5 min, cooled to
room temperature for 15 min, centrifuged at 13 000  g for 5 min,
and the supernatant recovered for PCR as DNA template. Primers
were as follows: for mefA, 50-AGT ATC ATT AAT CAC TAG TGC-30 and
50-TTC TTC TGG TAC TAA AAG TGG-30; ermB, 50-CGA GTG AAA AAG
TAC TCA ACC-30 and 50-AGT AAC GGT ACT TAA ATT GTT TAC-30;
ermTR, 50-ATA GAA ATT GGG TCA GGA AAA GG-30 and 50-CCC TGT
TTA CCC ATT TAT AAA CG-30.11 Ampliﬁcation was performed in a
DNA thermal cycler (GeneAmp, PCR System 9700; AppliedBiosystems) with the following conditions: For mefA and ermTR
genes: one cycle at 94 8C for 3 min; 30 cycles at 94 8C for 30 s; 50 8C
for 45 s; 72 8C for 90 s; and one cycle at 72 8C for 7 min. For ermB
gene: one cycle at 94 8C for 3 min; 30 cycles at 94 8C for 30 s; 45 8C
for 45 s; 72 8C for 90 s; and one cycle at 72 8C for 7 min.
Ampliﬁcation products were run on 1% agarose gels (100 V for
40–60 min) and stained with ethidium bromide. The product sizes
of the ermTR, ermB, and mefA genes were 500, 652, and 376 bp,
respectively (Figure 1).
3. Results
The 467 GAS strains from Mexico were from six states (Jalisco,
Durango, Aguascalientes, Morelos, Colima, and Nuevo Leon). The
174 GAS strains from the USA were from 23 states (Idaho,
Tennessee, Virginia, Minnesota, Montana, Georgia, Washington,
Utah, California, New York, Alabama, Texas, Alaska, Mississippi,
Massachusetts, Oregon, District of Columbia, Connecticut, Wyom-
ing, Maryland, Nevada, South Carolina, and North Carolina).
Of the strains from Mexico, all were isolated during the period
1999–2009 from patients ranging in age between 1 and 82 years
(median 8 years). The sites of isolation were as follows: 271/467
(58%) were from patients with acute pharyngitis, 89/467 (19%)
were from normally sterile sites (invasive), 57/467 (12%) were
from other non-sterile sites, and 50/467 (11%) were from
pharyngeal carriers.
Of the strains from the USA, all were isolated during the period
1999–2010 from patients aged between 5 and 91 years (median 41
years). In contrast to the GAS from Mexico, most of the USA strains
– 148/174 (85%) – were isolated from normally sterile sites
(invasive) (Table 1).
All strains were susceptible to penicillin, ceftriaxone, and
vancomycin. A single strain from Mexico was resistant to
clindamycin. Erythromycin resistance deﬁned as a MIC 1 mg/
ml by micro-broth dilution testing9 was found in 23 (4.9%)
Mexican strains and nine (5.2%) USA strains (Table 1). Phenotypes
of erythromycin-resistant strains identiﬁed in Mexico were M
Table 1
Demography and general characteristics of the GAS strains studied from patients with both invasive and non-invasive infections from Mexico and the USA
Mexico USA
Total of GAS strains 467 174
Period of isolates 1999–2009 1999–2010
Patients age range (years) 1–82 (median 8 years) 5–91 (median 41 years)
Invasive 89/467 (19%) 148/174 (85%)
Erythromycin resistance 23/467 (4.9%) 9/174 (5.2%)
Phenotypes M (95%); cMLS (5%) iMLS (33.3%); iMLS-D (33.3%); M (33.3%)
Erythromycin resistance-related genes mefA (95%); ermB (5%) ermTR (56%); mefA (33%); none (11%)
GAS, group A Streptococcus.
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the USA, phenotypes were iMLS (linked to ermTR) 33.3%, iMLS-D
(linked to ermTR) 33.3%, and M (linked to mefA) 33.3% (Figure 2).
Genes detected in erythromycin-resistant strains from Mexico
were mefA (95%) and ermB (5%). Strains from the USA harbored
ermTR (56%) and mefA (33%); no erythromycin resistance-related
genes were found in one strain out of the nine studied (i.e., 11%)
(Figure 3). In Mexico, all erythromycin-resistant strains belonged
to the non-invasive group, whereas 89% of strains from the USA
were from invasive cases.
4. Discussion
Since the ﬁrst description of erythromycin resistance in 1955,12
several reports have demonstrated a progressive increase in the
prevalence of erythromycin resistance worldwide; this increase has
been attributed to the use of erythromycin and other macrolides inFigure 3. Genes identiﬁed among erythromycin-resistant group A Streptococcus
strains isolated from patients with invasive and non-invasive infections; Mexico
and USA.
Figure 2. Phenotypes identiﬁed among erythromycin-resistant group A
Streptococcus strains isolated from patients with invasive and non-invasive
infections; Mexico and USA.the population.13–15 According to a review of trends in antibiotic
utilization in eight Latin American countries, Mexico ranked ﬁfth in
the consumption of macrolides, lincosamides and streptogramins
during 1997–2007.16 Despite this, the prevalence of erythromycin-
resistant strains isolated from 1999 to 2010 (4.9%) was similar to the
prevalence among strains from the USA (5.2%) during almost the
same period of time. This prevalence was also similar to that
reported in the USA during 2002–2003 (6–6.8%).11,17
Regarding the phenotypes isolated among GAS strains from
both Mexico and the USA, the M phenotype was predominant (95%
and 100%, respectively) in GAS strains isolated from non-invasive
infections and carriers. However, discordance between invasive
GAS isolates was marked between the two countries. Speciﬁcally,
19% (n = 89) of Mexican GAS strains were classiﬁed as invasive;
however none showed resistance to erythromycin. In contrast, 6%
of 148 invasive GAS from the USA demonstrated erythromycin
resistance. These erythromycin-resistant USA isolates were almost
exclusively of the inducible MLS phenotype (iMLS and iMLS-D;
75%). In total, these ﬁndings agree with other studies from the USA,
Italy, France, Mexico, Germany, India, and Austria that have also
reported a predominance of the M phenotype in non-invasive
isolates, and all the cited studies except the Mexican report have
described the iMLS phenotypes in the invasive ones.11,17–23
Our results also show that the mefA gene (always associated
with the M phenotype) was the most prevalent gene associated
with erythromycin-resistant strains isolated from patients with
non-invasive infections in both countries. This is also consistent
with other reports from elsewhere.18,20,23,24 The ermTR gene
(associated with iMLS and iMLS-D phenotypes) was the most
prevalent among GAS strains isolated from patients with invasive
infections in the USA. This association was also seen in Italy and
France.18,23 A single erythromycin-resistant strain from the USA
that belonged to an iMLS-D phenotype, showed none of the studied
erythromycin resistance-related genes. A possible explanation for
the presence of erythromycin resistance besides mefA, ermB, and
ermTR genes includes mutations of the 23S rRNA and the L4
ribosomal protein (not investigated).25,26
In summary, (1) the prevalence of erythromycin-resistant GAS
strains was low and comparable with other studies from Latin
America and the USA; (2) the M phenotype (always associated with
the mefA gene) was the most prevalent erythromycin-resistant
phenotype associated with non-invasive isolates; and (3) invasive
isolates demonstrating erythromycin resistance were only found
in strains from the USA; these were predominantly associated with
the inducible MLS phenotypes.
In conclusion, although the incidence of erythromycin resis-
tance among GAS is comparable between Mexico and the USA, the
mechanisms of erythromycin resistance are markedly different,
suggesting that geographic location and the relative incidence of
severe invasive GAS infection in the two countries inﬂuences the
prevalent strain phenotype and genotype. Evidence from this
study suggests that despite the close proximity of Mexico and the
USA, erythromycin-resistant GAS strains are not sharing some
erythromycin resistance genes. Since most (75%) of the erythro-
A. Villasen˜or-Sierra et al. / International Journal of Infectious Diseases 16 (2012) e178–e181 e181mycin-resistant GAS strains isolated from patients with invasive
infections in the USA also have inducible resistance to clinda-
mycin, physicians should consider alternative antibiotics for such
patients.
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